Elanco Animal Health

NutritionArticle

Elanco and Tonisity International form strategic partnership

Elanco and Tonisity have entered into a Distribution and Promotion Agreement in respect of Tonisity’s novel, gut enhancing porcine products.

ManagementArticle

Elanco awards three Care4Pigs grants

Three stand-out projects from Brazil, Switzerland and France, will be awarded grants from Elanco as part of its Care4Pigs initiative to further advance animal wellbeing.

Elanco Animal Health supports Stonehaven Incubate

Stonehaven Incubate, a business incubator that brings disruptive human health technologies to the animal sector, has received capital backing from the global animal health company Elanco Animal Health Incorporated.

Prevtec Microbia to be Acquired by Elanco

Deal supports development of Prevtec Microbia’s pipeline and product expansion

Lilly to Separate Elanco Animal Health with Initial Public Offering

Eli Lilly and Company today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission (SEC) for a potential initial public offering (IPO) of a minority ownership stake in Elanco as a separate company.

Elanco Animal Health introduces new respiratory PRRS vaccine

Prevacent PRRS is a timely and effective solution for to meet the PRRS challenges producers are facing today.

Five million doses of Prevtec Microbia’s bivalent vaccine Coliprotec^® F4/F18 Sold in the European Union

The product is a live bacterial vaccine containing a combination of two non-pathogenic E. coli strains for active immunization of pigs against PWD.

Elanco: The European Commission Authorises the Marketing of Prevtec Microbia’s Coliprotec® F4

Coliprotec® F4 will be distributed in the European Union by Elanco Animal Health (Elanco), a major player in the animal health industry doing business in more than 75 countries.

1 1

Lilly Finalizes Novartis Animal Health Acquisition

Eli Lilly and Company today announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry.

Lilly Announces Agreement to Acquire Novartis Animal Health

- $5.4 billion deal creates world’s second-largest animal health company. - Combination will increase Elanco’s product portfolio, expand its global commercial presence, and enhance manufacturing and R&D capabilities. - Combined organization is committed to leading the animal health industry in delivering innovation and customer value.

Elanco Announces Agreement to Acquire Lohmann Animal Health

Deal Provides Elanco with a leading manufacturer of feed additives and poultry vaccines.

Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp.

Deal will provide Elanco with feed enzyme products; underscores commitment to animal productivity.

Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health

Deal Would Provide European Expansion and Portfolio Diversification For Elanco, Lilly's Animal Health Division